OCX

The Eclipse Foundation Unveils Open Community Experience (OCX), Europe’s Premier Event for Open Source Innovation

Retrieved on: 
Thursday, April 18, 2024
Eclipse, Diamond, IDE, Java, Conference, Artificial intelligence, Proposal, Call, OCX, Community, Video game

Open Community for Java: focusing on topics related to Jakarta EE, Adoptium, MicroProfile, open source enterprise Java, and more.

Key Points: 
  • Open Community for Java: focusing on topics related to Jakarta EE, Adoptium, MicroProfile, open source enterprise Java, and more.
  • EclipseCon: the centre of gravity for all topics related to the Eclipse IDE platform and next-generation cloud-based development tools.
  • OCX offers the ideal opportunity to engage with developers, executives, and evangelists shaping today’s most advanced open technologies.
  • Join us in shaping the future of open source collaboration at OCX!

Oncocyte Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, April 12, 2024
Kidney, IP, Bio-Rad Laboratories, Research, Security (finance), Partnership, OCX, Eastern Time Zone, Marketing, Telephone, Cryptocurrency

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

Key Points: 
  • IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.
  • Q1 2024 cash burn, respectively
    “In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP,” said Josh Riggs, CEO of Oncocyte.
  • For Oncocyte’s complete financial results for the year ended December 31, 2023, see the Company’s annual Form 10-K to be filed with the Securities and Exchange Commission on April 15, 2024.
  • Oncocyte will host a conference call to discuss fourth quarter and full year 2023 financial results prior to market open on Friday, April 12, 2024 at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Friday, April 12, 2024
Sale, Regulation D, Security (finance), Act, OCX, Needham & Company

The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.

Key Points: 
  • The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
  • The private placement is expected to close on or about April 15, 2024, subject to the satisfaction of customary closing conditions.
  • Needham & Company is acting as the exclusive placement agent for the private placement.
  • The gross proceeds to the Company from the private placement are expected to be approximately $15.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Retrieved on: 
Thursday, April 11, 2024
FDA, Bio-Rad Laboratories, Security (finance), Partnership, Research, DdPCR, PCR, Transplant, OCX, IVD, Pharmaceutical industry

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the commercialization of its research use only GraftAssure™ assay, powered by Droplet Digital™ PCR (ddPCR™)*. The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.

Key Points: 
  • The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.
  • As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead.
  • Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights.
  • Additionally, Bio-Rad has been granted an option for IVD commercial rights at FDA clearance, subject to meeting specific objectives.

2023 in Review: Eclipse Software Defined Vehicle (SDV) Accelerates Automotive Tech Innovation through Open Source Collaboration

Retrieved on: 
Tuesday, February 27, 2024
General Motors, Research, IEC 61508, Growth, Future, HARMAN, Certification, OCX, Software, ISO, Eclipse Foundation, Automotive industry, GM, ISO 26262, Ecosystem, LG Electronics, IEC, Community, Development, Microsoft, Partnership, European Commission, Commercial software, Original equipment manufacturer, DENSO, Civil service commission, Electronics, Innovation, IEC 62304, SDV, G6, Volkswagen Group, Renewable energy

The year marked several noteworthy highlights, showcasing our unwavering commitment to innovation in the automotive tech landscape:

Key Points: 
  • The year marked several noteworthy highlights, showcasing our unwavering commitment to innovation in the automotive tech landscape:
    Inaugural Automotive Open Source Summit Success:
    In early June, Eclipse SDV successfully launched its first-ever Automotive Open Source Summit .
  • Geared towards automotive tech executives, thought leaders and senior managers, the summit showcased speakers from Eclipse automotive initiatives and beyond.
  • Discover opportunities to actively contribute to the global centre of gravity for software defined vehicle innovation and collaboration.
  • Later this year, the Eclipse Foundation will be hosting its inaugural event focused on automotive open source at the Open Code for Automotive conference, co-located with its newest global event for open source software, the Open Code Experience (OCX) , taking place on 22-24, October 2024 in Mainz, Germany.

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Retrieved on: 
Tuesday, January 16, 2024
OCX, Condado Vanderbilt Hotel

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024.

Key Points: 
  • IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024.
  • The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
  • For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/

CoreSite Recognized as a Finalist in the Gartner® 2023 Eye on Innovation Awards for Communication Service Providers for The Americas

Retrieved on: 
Tuesday, January 16, 2024
Data Management, Technology, Software, Networks, Internet, Hardware, Cloud, The Economist, American Tower, Benchmarking, CoreSite, OCX

CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”), today announced that it was selected as a finalist in the 2023 Eye on Innovation Awards for Communication Service Providers for the Americas region .

Key Points: 
  • CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”), today announced that it was selected as a finalist in the 2023 Eye on Innovation Awards for Communication Service Providers for the Americas region .
  • The Open Cloud Exchange® (OCX) was among the finalists for the award which “recognizes communications service providers (CSPs) for their innovative use of technology to drive best-in-class initiatives.
  • 1 Gartner, 2023 Gartner Eye on Innovation Awards for Communications Service Providers, https://www.gartner.com/en/about/awards/communications-eye-on-innovation
    GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission.
  • The identification of a Gartner award winner or finalist is not an endorsement by Gartner of any company, vendor, product or service.

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Retrieved on: 
Wednesday, December 6, 2023
FDA, Medical device, 2005 in television, Public, IVD, OCX, Patient, Diagnosis, PMA, De novo

IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte within the recent proposed rule from the FDA that seeks to oversight LDTs and puts its lab-developed tests and kitted products on parallel paths.

Key Points: 
  • IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays.
  • This move positions Oncocyte within the recent proposed rule from the FDA that seeks to oversight LDTs and puts its lab-developed tests and kitted products on parallel paths.
  • “Establishing our VitaGraft Assay Lab Developed Test as a regulated device is good for patients and is a key part of our regulatory strategy,” said Josh Riggs, CEO of Oncocyte.
  • Having a predicate in place can significantly reduce the time and complexity of follow-on submissions to the FDA.

CoreSite Enables 50G Multicloud Networking on the Open Cloud Exchange® with Enhanced Virtual Connections to Oracle Cloud Infrastructure FastConnect

Retrieved on: 
Thursday, December 7, 2023
Data Management, Technology, Telecommunications, Software, Networks, Artificial Intelligence, Internet, Cloud, American Tower, Data management, Open Cloud Computing Interface, NYSE, CoreSite, Oracle Cloud, Artificial intelligence, Machine learning, Oracle, AI, OCX, OCI, Data-rate units, OPN, VMware, SVP, Mobile phone, Video game

Oracle customers can use these connections to harness the power of Oracle Cloud Infrastructure (OCI) locally, including services like Oracle Autonomous Database, to unlock innovation and drive business growth.

Key Points: 
  • Oracle customers can use these connections to harness the power of Oracle Cloud Infrastructure (OCI) locally, including services like Oracle Autonomous Database, to unlock innovation and drive business growth.
  • With the launch of the new OCX capabilities to FastConnect, businesses can gain greater flexibility to provision on-demand, secure bandwidth to OCI with virtual connections of up to 50 Gbps.
  • In addition, OCI’s distributed cloud offers multicloud, hybrid cloud, public cloud, and dedicated cloud options to help customers harness the benefits of cloud with greater control over data residency, locality, and authority, even across multiple clouds.
  • The new Open Cloud Exchange capabilities on FastConnect will be available in Q4 2023.

Military GNSS Anti-Jamming Systems Market and Technology Forecast Report 2023-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Engineering, Defense, Satellite, Technology, Manufacturing, Military, Government Technology, PNT, Technology forecasting, Navigation, GNSS, Assurance, Algorithm, Satellite navigation, Orangi Pilot Project, Atmosphere, Aircraft, OCX, Channel Technologies Group, Satellite navigation device, Timing

The "Military GNSS Anti-Jamming Systems - Market and Technology Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Military GNSS Anti-Jamming Systems - Market and Technology Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive study delves into the global military GNSS anti-jamming market, offering detailed insights and forecasts for the next eight years.
  • The report covers market size estimations, examines crucial technological advancements, and analyzes market trends driving the demand for military GNSS anti-jamming systems.
  • As military platforms increasingly rely on GNSS (Global Navigation Satellite Systems), the threat of jamming and interference devices has grown.